Trimedyne, Inc.'s Chairman Interviewed by Chartpoppers.com
LAKE FOREST, CA--(Marketwire - March 30, 2010) - TRIMEDYNE, INC. (OTCBB: TMED) today announced its chairman, Marvin P. Loeb, Sc.D., was interviewed live by Carl Marek of ChartPoppers.Com
The interview will be available for one month commencing on Tuesday, March 30, 2010. To read this detailed, comprehensive interview directly, simply click on: www.chartpoppers.com.
Dr. Loeb discussed the Company's earlier reported increases in revenues and new product, its business and markets, as well as other matters.
Commenting on the interview, Dr. Loeb said, "We are pleased that CEO/CFO is advising the investment community of the potential of Trimedyne's outpatient laser procedures to treat herniated or ruptured discs in the spine, enlarged prostates in men and other conditions."
About ChartPoppers.Com
ChartPoppers.Com is a worldwide online publication featuring corporate news and live interviews with CEOs and CFOs of promising companies by skilled analyst interviewers to bring better market insight to investors. ChartPoppers' interviews are displayed prominently by many search engines.
About Trimedyne
Trimedyne, Inc. is a leading manufacturer of proprietary medical lasers and patented fiber optic devices for performing a variety of minimally invasive procedures as a less traumatic, lower cost alternative to traditional surgery. For additional information, visit Trimedyne's website at http://www.trimedyne.com.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:
Statements in this news release and the above mentioned interview may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "expect", "may", "could" and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's Form 10-K-SB for the year ended September 30, 2009 and subsequently filed SEC reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.